Market capitalization | $258.22m |
Enterprise Value | $171.29m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 5.63 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-60.75m |
Free Cash Flow (TTM) Free Cash Flow | $-50.72m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
5 Analysts have issued a Abeona Therapeutics, Inc. forecast:
5 Analysts have issued a Abeona Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -3.83 -3.83 |
4,888%
4,888%
|
|
EBITDA | -57 -57 |
31%
31%
|
EBIT (Operating Income) EBIT | -61 -61 |
29%
29%
|
Net Profit | -71 -71 |
83%
83%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
Head office | United States |
CEO | Vishwas Seshadri |
Employees | 84 |
Founded | 1974 |
Website | www.abeonatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.